-
Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand
•
China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended for the manufacturing of its mRNA-based COVID-19 vaccine. This decision comes in response to an anticipated lack of sufficient market demand. According to a Reuters report, Stemirna had initiated testing production at the site but…
-
BGI Genomics Partners with Thai Entities to Combat Thalassemia through Genomics and Cell Therapy
•
China-based genomics leader BGI Genomics Co., Ltd (SHE: 300676) has entered into a memorandum of understanding (MOU) with Thailand’s Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Genomics Innovation Public Company Limited, and Hemogen Hongkong Alpha Technology., Ltd. The collaboration aims to enhance the prevention and treatment of Thalassemia and…
-
Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration (NMPA) has accepted its filing for an additional indication of Tuoyi (toripalimab). The drug is proposed to be used in combination with etoposide and platinum for the treatment of extensive stage small cell…
-
Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case
•
Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against the assertion that its generic version of AstraZeneca’s (AZ, NASDAQ: AZN) type 2 diabetes therapy, Forxiga (dapagliflozin), infringed upon a patent listed by AstraZeneca on the Center for Drug Evaluation (CDE)’s drug patent registration platform,…
-
Boyu Capital Acquires Hong Kong Medical Device Company Quasar for Over $600 Million
•
Boyu Capital, according to a Bloomberg report, is set to acquire Quasar, a Hong Kong-based medical device company. The acquisition deal is valued at over USD 600 million, reflecting Quasar’s current market capitalization. The transaction is anticipated to close imminently, with the support of Quasar’s extensive healthcare clients globally. Quasar’s…
-
Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth
•
Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second quarter of 2023, with both sales and profits surpassing analyst forecasts. Net sales for the quarter reached USD 13.622 billion, marking a 9% year-on-year (YOY) increase in constant currency terms. Core net income also saw…
-
Shanghai Pharmaceuticals and Mindray Form Strategic Alliance for Medical Equipment and IVD Products
•
Shanghai Pharmaceuticals (SHA: 601607, HKG: 2607), a leading pharmaceutical company in China, has announced a long-term partnership with fellow Chinese medical device firm Mindray (SHE: 300760). The collaboration will focus on medical equipment, medical consumables, and in vitro diagnostic (IVD) products. The two companies plan to integrate their existing resources…
-
MindRank Ltd Secures Over $20 Million in Series A+ Funding to Advance AI Drug Development
•
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd has reportedly secured more than USD 20 million in a Series A+ financing round. Cherami Investment led the investment, which will be utilized to enhance drug development efforts and to upgrade and commercialize the company’s AI drug development platform. Upgrading the AI…
-
Zhejiang Dian Diagnostics Partners with Northeast Infectious Diseases Alliance to Enhance Surveillance
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics specialist based in China, has entered into a strategic partnership with the Northeast Infectious Diseases Alliance. The collaboration aims to establish a standardized three-level monitoring system for infectious diseases, enhancing the capabilities of central monitoring hospitals and bolstering the region’s…
-
Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a preclinical stage biotech company jointly incubated by Viva Biotech Holdings (HKG: 1873). The transaction includes a USD 500 million upfront payment and potential additional payments of up to USD 500 million upon the achievement of…
-
Allen Institute for Immunology Partners with Eli Lilly to Study Atopic Dermatitis and Rheumatoid Arthritis
•
The US-based Allen Institute for Immunology has announced a strategic partnership with compatriot company Eli Lilly (NYSE: LLY) to delve into the research of disease state diversity and drug response-predicting biomarkers, specifically focusing on atopic dermatitis and rheumatoid arthritis (RA). This collaboration represents the first industry partnership for the immune-related…
-
Pfizer and Flagship Pioneering Invest $100 Million in Drug Candidates Development
•
Global pharmaceutical giant Pfizer (NYSE: PFE) and venture capital firm Flagship Pioneering have this week announced a joint commitment to invest USD 50 million each into the development of 10 drug candidates. Pfizer retains the option to acquire these candidates, while Flagship stands to collect up to USD 700 million…
-
Qihan Biotech’s QN-019a Receives Clinical Clearance for Gene-Edited iPSC-Derived Cell Therapy in China
•
Hangzhou Qihan Biotech Co., Ltd., a leading specialist in xenotransplantation based in China, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its product QN-019a. This marks the first Investigational New Drug (IND) approval in China for a gene-edited induced pluripotent stem cell…
-
Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project
•
This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN), Bayer (ETR: BAYN), and Merck have committed to funding the whole-genome sequencing (WGS) of 250,000 individuals. This significant commitment is in support of the Alliance for Genomic Discovery (AGD), a partnership led by Illumina (NASDAQ:…
-
Sumitomo Pharma to Invest $30 Million in China for New Product Development
•
Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of USD 30 million in the China market, as reported by Shine. This investment, as stated by Yoshitaka Koketsu, president and CEO of Sumitomo Pharma (China) Co., Ltd, is aimed at developing and launching new products…
-
Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab
•
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in its Phase I ERASER study. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ATG-017 in combination with nivolumab for the treatment of advanced solid tumors. The trial is conducted…
-
Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a clinical trial filing for its Category 1 investigational drug, HYP-2090PTSA. This small molecule drug candidate targets KRAS G12C and PI3K and is under review for potential use…
-
Puncture Robotic Secures $13.9 Million in Series A+ Funding to Advance Medical Robotics
•
Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD 13.9 million) in a Series A+ financing round. The round was led by Shenzhen Capital Group, with participation from Huayi Capital. The funds raised will be allocated towards product research and development, clinical validation, enhancement…
-
Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus
•
France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has received marketing approval from the US Food and Drug Administration (FDA) for their codeveloped drug, Beyfortus (nirsevimab). The drug is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in…
-
Cutia Therapeutics’ CU-40101 Completes Phase I Clinical Trial for Androgenetic Alopecia
•
Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced the completion of the Phase I clinical study for its potential Category 1 drug, CU-40101. This small-molecule thyroid hormone receptor agonist liniment is intended for external use in treating androgenic alopecia. While the full statistical analysis of the trial…
